NeuroPace (NPCE) announced FDA submission of three-year safety and effectiveness data from its prospective post-approval study of the RNS System in adults with drug-resistant focal epilepsy. The study enrolled more than three hundred patients from more than thirty leading Level 4 Comprehensive Epilepsy Centers in the United States, making it the largest prospectively enrolled trial in the field of neuromodulation for drug-resistant focal epilepsy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.